cryptocurrency types of coins, Reviews

Modern Pharmaceuticals: Sinopharm Zhijun, the holding subsidiary, obtained the drug registration certificate of Cefotaxime Tablets. Modern Pharmaceuticals announced that Sinopharm Zhijun Pharmaceutical Co., Ltd., the holding subsidiary, recently received the Drug Registration Certificate of Cefotaxime Tablets approved and issued by National Medical Products Administration. Cefopoxime axetil tablets are the third generation cephalosporins taken orally, which are used to treat upper respiratory tract infections and lower respiratory tract infections caused by sensitive bacteria. In 2023, the global sales of preparations will be USD 370 million, and the sales of public hospitals nationwide will be RMB 102 million. The accumulative R&D investment of Sinopharm Zhijun is about RMB 28.45 million. Obtaining the registration certificate will enrich the company's product line, increase market competitiveness and have a positive impact on the company's future development. However, drug sales are easily affected by factors such as policies and market environment, and there are uncertainties.Zhengshang Institute: Xinfengming Jiangsu Xintuo New Materials Co., Ltd. was added as the designated short fiber delivery warehouse. Zhengzhou Commodity Exchange announced on the 11th that after research, Xinfengming Jiangsu Xintuo New Materials Co., Ltd. was added as the designated short fiber delivery warehouse, and the short fiber futures delivery business was started from the date of announcement, with the daily minimum delivery speed of 1,000 tons/day and the premium of 0 yuan/ton.South Korea's opposition parties condemned Yin Xiyue's office for preventing the police from searching.

Kanglongda: The company's products have not been directly sold to humanoid robots and aerospace manufacturing-related enterprises. Kanglongda said on the interactive platform on December 11 that the ultra-high molecular weight polyethylene (UHMWPE) fibers produced by the company are mainly used for industrial synergy, and the products sold abroad are mainly used in the fields of national defense and police, rope nets and belts. Up to now, the company's products have not been directly sold to humanoid robots and aerospace manufacturing related enterprises.As of the close of early trading, the Nikkei 225 index fell by 0.65% and the Dongzheng index fell by 0.2%.European bond market: The market remained stable before the US inflation data was released, waiting for the ECB meeting on Thursday. On Wednesday, the European bond market remained stable, waiting for the US consumer price index (CPI) data later that day and the ECB meeting on Thursday. The yield of German 10-year government bonds did not change much, at 2.12%. Traders are waiting for the US CPI inflation data released at 21: 30 Beijing time on Wednesday, which may affect the market expectation that the Fed will cut interest rates next week. The yield of Italian 10-year government bonds also remained basically unchanged at 3.20%, and the spread between Italian government bonds and German government bonds remained at 108 basis points. The market expects the European Central Bank to cut interest rates by 25 basis points on Thursday. The yield of German two-year government bonds is sensitive to the interest rate expectations of the European Central Bank, falling by 1 basis point to 1.96%.

Modern Pharmaceuticals: Sinopharm Zhijun, the holding subsidiary, obtained the drug registration certificate of Cefotaxime Tablets. Modern Pharmaceuticals announced that Sinopharm Zhijun Pharmaceutical Co., Ltd., the holding subsidiary, recently received the Drug Registration Certificate of Cefotaxime Tablets approved and issued by National Medical Products Administration. Cefopoxime axetil tablets are the third generation cephalosporins taken orally, which are used to treat upper respiratory tract infections and lower respiratory tract infections caused by sensitive bacteria. In 2023, the global sales of preparations will be USD 370 million, and the sales of public hospitals nationwide will be RMB 102 million. The accumulative R&D investment of Sinopharm Zhijun is about RMB 28.45 million. Obtaining the registration certificate will enrich the company's product line, increase market competitiveness and have a positive impact on the company's future development. However, drug sales are easily affected by factors such as policies and market environment, and there are uncertainties.Zhengshang Institute: Xinfengming Jiangsu Xintuo New Materials Co., Ltd. was added as the designated short fiber delivery warehouse. Zhengzhou Commodity Exchange announced on the 11th that after research, Xinfengming Jiangsu Xintuo New Materials Co., Ltd. was added as the designated short fiber delivery warehouse, and the short fiber futures delivery business was started from the date of announcement, with the daily minimum delivery speed of 1,000 tons/day and the premium of 0 yuan/ton.European stocks opened lower, European Stoxx 50 index fell 0.15%, European stocks opened lower, European Stoxx 50 index fell 0.15%, German DAX index fell 0.03%, British FTSE 100 index fell 0.3%, and French CAC40 index fell 0.3%.